Panoramic Capital LLC Purchases New Stake in Axsome Therapeutics, Inc. $AXSM

Panoramic Capital LLC acquired a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 44,000 shares of the company’s stock, valued at approximately $10,770,000. Axsome Therapeutics comprises approximately 4.6% of Panoramic Capital LLC’s holdings, making the stock its 6th largest holding. Panoramic Capital LLC owned about 0.08% of Axsome Therapeutics as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the stock. Kemnay Advisory Services Inc. purchased a new stake in shares of Axsome Therapeutics during the 4th quarter worth approximately $31,000. Ameriflex Group Inc. purchased a new position in Axsome Therapeutics in the fourth quarter valued at approximately $37,000. Hollencrest Capital Management lifted its stake in Axsome Therapeutics by 400.0% in the first quarter. Hollencrest Capital Management now owns 200 shares of the company’s stock valued at $34,000 after purchasing an additional 160 shares during the last quarter. ABS Investment Management LLC bought a new position in Axsome Therapeutics during the second quarter valued at $171,339,000. Finally, Silvant Capital Management LLC bought a new position in Axsome Therapeutics during the second quarter valued at $66,000. Institutional investors own 81.49% of the company’s stock.

Insider Buying and Selling

In other news, CFO Nick Pizzie sold 33,000 shares of the company’s stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $240.09, for a total transaction of $7,922,970.00. Following the sale, the chief financial officer directly owned 42,867 shares in the company, valued at $10,291,938.03. This represents a 43.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Herriot Tabuteau sold 49,670 shares of the stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $241.01, for a total transaction of $11,970,966.70. Following the completion of the sale, the chief executive officer directly owned 7,229 shares in the company, valued at approximately $1,742,261.29. The trade was a 87.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 200,766 shares of company stock worth $46,685,646 over the last quarter. 20.60% of the stock is owned by corporate insiders.

Key Axsome Therapeutics News

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating on Axsome Therapeutics, signaling continued confidence in the company’s long-term commercial outlook despite lowering its earnings forecasts.
• Neutral Sentiment: The firm continues to project a significant improvement in profitability in 2027, with positive earnings expected beginning in the second quarter and full-year 2027 EPS forecast at $5.25.
• Neutral Sentiment: A report showing zero short interest as of August 25 does not indicate meaningful short-selling pressure, although the data appears inconsistent because it also reports no change from the prior period.
• Negative Sentiment: HC Wainwright reduced its FY2026 EPS estimate to a loss of $4.10 from a loss of $3.89, while cutting forecasts for third-quarter and fourth-quarter 2026 EPS to losses of $0.95 and $0.91, respectively.
• Negative Sentiment: The analyst also lowered its 2027 estimates: first-quarter EPS was revised to a $0.27 loss from $0.05 in earnings, second-quarter EPS to $1.06 from $1.30, third-quarter EPS to $1.92 from $2.30, and full-year EPS to $5.25 from $6.47. Fourth-quarter 2027 EPS was reduced to $2.53 from $2.81.

Axsome Therapeutics Trading Up 0.8%

NASDAQ:AXSM opened at $207.15 on Thursday. Axsome Therapeutics, Inc. has a 1 year low of $112.90 and a 1 year high of $260.19. The stock’s fifty day moving average price is $229.34 and its two-hundred day moving average price is $206.61. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.43 and a quick ratio of 1.34. The company has a market cap of $10.85 billion, a P/E ratio of -55.24 and a beta of 0.65.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.10). The company had revenue of $218.38 million during the quarter, compared to analysts’ expectations of $221.11 million. Axsome Therapeutics had a negative net margin of 24.68% and a negative return on equity of 265.55%. As a group, analysts expect that Axsome Therapeutics, Inc. will post -2.8 EPS for the current year.

Analyst Ratings Changes

AXSM has been the topic of several research reports. Morgan Stanley boosted their target price on Axsome Therapeutics from $242.00 to $251.00 and gave the company an “equal weight” rating in a research note on Tuesday, August 11th. HC Wainwright reissued a “buy” rating on shares of Axsome Therapeutics in a report on Monday. Truist Financial upgraded Axsome Therapeutics to a “strong-buy” rating in a research note on Monday, June 15th. Robert W. Baird upped their price objective on shares of Axsome Therapeutics from $241.00 to $246.00 and gave the company an “outperform” rating in a report on Tuesday, May 5th. Finally, Needham & Company LLC increased their target price on shares of Axsome Therapeutics from $267.00 to $268.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $267.60.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.